Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Enfuvirtide cerebrospinal fluid (CSF) pharmacokinetics and potential use in defining CSF HIV-1 origin.

Price RW, Parham R, Kroll JL, Wring SA, Baker B, Sailstad J, Hoh R, Liegler T, Spudich S, Kuritzkes DR, Deeks SG.

Antivir Ther. 2008;13(3):369-74.

2.

Enfuvirtide: a fusion inhibitor for the treatment of HIV infection.

Fung HB, Guo Y.

Clin Ther. 2004 Mar;26(3):352-78. Review.

PMID:
15110129
3.

[Enfuvirtide: first drug of a new family of antiretroviral agents].

Espona M, Ferrández O, Grau S, Carmona A.

Farm Hosp. 2005 Nov-Dec;29(6):375-83. Review. Spanish.

4.

Enfuvirtide, the first fusion inhibitor to treat HIV infection.

Poveda E, Briz V, Soriano V.

AIDS Rev. 2005 Jul-Sep;7(3):139-47. Review.

PMID:
16302461
5.

Enfuvirtide antiviral activity despite rebound viremia and resistance mutations: fitness tampering or a case of persistent braking on entering?

Morse C, Maldarelli F.

J Infect Dis. 2007 Feb 1;195(3):318-21. Epub 2006 Dec 21. Review. No abstract available.

PMID:
17205468
6.

Resistance to enfuvirtide, the first HIV fusion inhibitor.

Greenberg ML, Cammack N.

J Antimicrob Chemother. 2004 Aug;54(2):333-40. Epub 2004 Jul 1. Review.

PMID:
15231762
7.
8.

Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid).

Else LJ, Taylor S, Back DJ, Khoo SH.

Antivir Ther. 2011;16(8):1139-47. doi: 10.3851/IMP1918. Review.

PMID:
22155898
9.

Enfuvirtide: from basic investigations to current clinical use.

Joly V, Jidar K, Tatay M, Yeni P.

Expert Opin Pharmacother. 2010 Nov;11(16):2701-13. doi: 10.1517/14656566.2010.522178. Review.

PMID:
20977403
10.

Reassessment of enfuvirtide's role in the management of HIV-1 infection.

Marr P, Walmsley S.

Expert Opin Pharmacother. 2008 Sep;9(13):2349-62. doi: 10.1517/14656566.9.13.2349 . Review.

PMID:
18710359
11.

Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development.

Cooper DA, Lange JM.

Lancet Infect Dis. 2004 Jul;4(7):426-36. Review.

PMID:
15219553
13.

[Enfuvirtide, mechanism of action and pharmacological properties].

Kapić E, Becić F, Zvizdić S.

Med Arh. 2005;59(5):313-6. Review. Bosnian.

PMID:
16134757
14.

[Mechanisms of cerebral damage in patients with HIV-infection].

Beliakov NA, Medvedev SV, Trofimova TN, Rassokhin VV, Dement'eva NE, Shelomov SA.

Vestn Ross Akad Med Nauk. 2012;(9):4-12. Review. Russian.

PMID:
23210166
15.

Approach to cerebrospinal fluid (CSF) biomarker discovery and evaluation in HIV infection.

Price RW, Peterson J, Fuchs D, Angel TE, Zetterberg H, Hagberg L, Spudich S, Smith RD, Jacobs JM, Brown JN, Gisslen M.

J Neuroimmune Pharmacol. 2013 Dec;8(5):1147-58. doi: 10.1007/s11481-013-9491-3. Epub 2013 Aug 13. Review.

16.

Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections.

Nau R, Sörgel F, Eiffert H.

Clin Microbiol Rev. 2010 Oct;23(4):858-83. doi: 10.1128/CMR.00007-10. Review.

Supplemental Content

Support Center